Introduction
============

Nasopharyngeal carcinoma (NPC) is disproportionately common in southern China ([@b1-mco-0-0-1318]), where the annual incidence is 15--50/100,000 individuals ([@b2-mco-0-0-1318]). Radiotherapy (RT) is the primary treatment for NPC. While advances in tumor imaging and RT technologies have increased 5-year disease-free survival (DFS) to 77% for early-stage disease ([@b3-mco-0-0-1318]), distant metastasis remains a major obstacle to further improvements in survival ([@b4-mco-0-0-1318]).

The immune checkpoints proteins programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been reported to be important immunotherapy targets. The antitumor efficacy of blocking these targets has been confirmed *in vitro* as well as *in vivo*. Blocking the PD-1/PD-L1 signaling pathway represents a promising immunotherapeutic strategy to enhance the ability of the immune system to target cancer cells ([@b5-mco-0-0-1318],[@b6-mco-0-0-1318]).

PD-L1 is expressed in a variety of tumor types, including esophageal, gastrointestinal tract, pancreatic, breast, lung and kidney carcinomas ([@b7-mco-0-0-1318],[@b8-mco-0-0-1318]). Several studies have indicated that tumor PD-L1 expression is associated with poor prognosis ([@b9-mco-0-0-1318],[@b10-mco-0-0-1318]); however, it remains unclear whether such an association exists in NPC. The aim of the present study was to investigate the associations between tumor PD-L1 expression and prognosis in NPC.

Patients and methods
====================

### Patients and sample collection

Two cohorts of patients with NPC were enrolled: 62 patients with primary biopsy-confirmed NPC diagnosed between January 2009 and January 2012 at the Second Affiliated Hospital of Nanchang University (Nanchang, China) and 58 patients with primary biopsy-confirmed NPC diagnosed between January 2010 and May 2015 at the People\'s Hospital of Fuzhou (Fuzhou, China). Formalin-fixed paraffin-embedded tissues were obtained from the initial diagnostic biopsy specimens. Information on the clinical course of each patient, including sex, age, tumor staging and smoking history, was obtained from medical records. Complete follow-up data were available for all 62 patients treated at the Second Affiliated Hospital of Nanchang University. Data on disease and vital status for these patients were obtained using a prospectively-maintained hospital tumor registry. The study protocol was approved by the Medical Ethics Committees of the Second Affiliated Hospital of Nanchang University and the People\'s Hospital of Fuzhou.

### Immunohistochemistry

Immunohistochemical staining for the PD-L1 protein was performed using sections prepared from the formalin-fixed diagnostic samples. Briefly, 4-µm sections were deparaffinized in xylene and rehydrated through a graded ethanol series to distilled water. After processing via routine procedures, the sections were incubated overnight at 4°C with rabbit anti-PD-L1 antibody (E1L3 N™, catalog no. 13684, Cell Signaling Technology Inc., Shanghai, China) diluted 1:100 in blocking solution, followed by incubation with a horseradish peroxidase-conjugated secondary antibody (MaxVision Immunohistochemical Detection kit, rabbit/mouse, 1:100 dilution, catalog no. 5001, MaxVision Biosciences, Inc., Fuzhou, China) according to the manufacturer\'s instructions. After washing, color was developed by incubation in 3,3′-diaminobenzidine tetrahydrochloride, followed by hematoxylin counterstaining.

The staining was independently assessed by two surgical pathologists using a semi-quantitative scale that ranges from 0 to 100% for the proportion of PD-L1-positive cancer cells. The mean score for replicate samples was recorded. Two groups of patients were created based on receiver operating characteristic (ROC) curves. According to the results, 20% was set as the cut-off value for dividing the samples into high PD-L1 and low PD-L1 group for DFS. The areas under the ROC curves were 0.827.

### Statistical analysis

The associations between PD-L1 expression and clinicopathological characteristics were assessed using Pearson\'s χ2 test. Overall survival (OS) and DFS were compared using the Kaplan-Meier method and log-rank tests. Cox proportional hazards analysis was performed to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate the associations between tumor PD-L1 expression and survival outcome. Multivariate survival analysis was conducted for all of the parameters using the Cox regression model. All analyses were performed using SPSS software, version 13.0 (SPSS Inc., Chicago, IL, USA). Two-sided P-values \<0.05 were considered to indicate statistically significant differences.

Results
=======

### Clinicopathological characteristics

The 120 patients in this cohort ranged in age from 17 to 69 years (median, 48 years). A total of 78% (79/102) of the patients had stage I--III and 22% (23/102) had stage IV NPC according to the 1997 American Joint Committee on Cancer staging system ([@b11-mco-0-0-1318]). All the cases were classified as undifferentiated non-keratinizing NPC. The estimated 5-year OS and DFS rates for the group eligible for survival analysis (the 62 patients treated at the Second Affiliated Hospital of Nanchang University) were 87.5 and 70.1%, respectively. Other clinicopathological characteristics are summarized in [Table I](#tI-mco-0-0-1318){ref-type="table"}.

### PD-L1 protein is frequently expressed in NPC

To investigate whether PD-L1 is expressed in NPC similar to its expression in other tumors, PD-L1 protein expression was assessed using immunohistochemistry in tumor samples from 120 patients with NPC. The PD-L1 protein was found to be frequently expressed in NPC. PD-L1 expression was detected in 71% (85/120) of the tumor samples. The PD-L1 protein was localized to the cell membrane of the primary tumor cells ([Fig. 1A](#f1-mco-0-0-1318){ref-type="fig"}) and metastatic lymph nodes ([Fig. 1D](#f1-mco-0-0-1318){ref-type="fig"}). Moreover, PD-L1 protein expression was significantly higher in the tumor cells compared with that in adjacent non-cancerous tissues ([Fig. 1B and C](#f1-mco-0-0-1318){ref-type="fig"}).

### Associations between PD-L1 expression and the clinicopathological characteristics of NPC

To identify the clinical relevance of PD-L1 expression in NPC, the associations between PD-L1 expression and clinicopathological characteristics of NPC, such as sex, age, smoking history, histology and TNM stage, were examined. The 120 patients were further classified into the high PD-L1 (n=54) and low PD-L1 (n=66) groups based on the tumor PD-L1 expression level. The results revealed that high PD-L1 expression was significantly associated with age (P=0.006) and stage (P=0.036), but not the other clinical characteristics examined ([Table I](#tI-mco-0-0-1318){ref-type="table"}).

### Associations between PD-L1 expression and prognosis in NPC

Estimated 5-year OS and DFS for the group eligible for survival analysis (the 62 patients treated at Second Affiliated Hospital of Nanchang University) were 87.5 and 70.1%, respectively ([Fig. 2A and B](#f2-mco-0-0-1318){ref-type="fig"}). The OS and DFS curves for the high PD-L1 and low PD-L1 groups are shown in [Fig. 2C and D](#f2-mco-0-0-1318){ref-type="fig"}. As expected, patients with high PD-L1 expression had significantly poorer OS (P=0.023) and DFS (P=0.002) compared with patients with low PD-L1 expression. Univariate Cox proportional regression analysis revealed that T stage (HR=4.081, 95% CI: 1.130--18.14; P=0.048) and PD-L1 expression (HR=0.163, 95% CI: 0.044--0.600; P=0.006) were prognostic factors for DFS ([Table II](#tII-mco-0-0-1318){ref-type="table"}). A multivariate analysis using the Cox regression model revealed that T stage (HR=8.190, 95% CI: 1.355--18.152; P=0.023) and PD-L1 expression level (HR=0.124, 95% CI: 0.031--0.509; P=0.001) served as independent prognostic factors for DFS.

Discussion
==========

Tumor immune evasion is considered to be a hallmark of cancer ([@b12-mco-0-0-1318]). Blockade of immune checkpoints represents a promising therapeutic approach to activate antitumor immunity ([@b13-mco-0-0-1318]). PD-L1 is recognized as an important immunosuppressive factor ([@b14-mco-0-0-1318]) and is upregulated in a variety of Epstein-Barr virus (EBV)-associated malignancies ([@b15-mco-0-0-1318]), although its expression in NPC, an EBV-associated malignancy with a higher metastatic potential compared with other head and neck cancers, is poorly characterized ([@b16-mco-0-0-1318],[@b17-mco-0-0-1318]). The expression of PD-L1 is associated with the treatment response to nivolumab, an anti-PD-1 antibody, in a subset of tumor types ([@b18-mco-0-0-1318]). The efficacy of immune-targeted therapies in EBV-associated malignancies requires further investigation. Therefore, assessing the expression of biomarkers such as PD-L1 may help identify patients who will benefit from immunomodulatory agents. However, variation in PD-L1 expression rates previously observed in a study of various cancers has been attributed to differences in cut-off values, antibodies, and study populations ([@b19-mco-0-0-1318],[@b20-mco-0-0-1318]). In lung cancer characterized by PD-L1 expression, the expression rates varied from 24 to 60% using the same 5% cut-off value ([@b21-mco-0-0-1318],[@b22-mco-0-0-1318]), and from 21 to 95 % according to different cut-off values of 1, 10 and 50% ([@b23-mco-0-0-1318],[@b24-mco-0-0-1318]). Thus, the use of PD-L1 expression as a marker remains controversial due to the different antibodies used, the method of assessment and the different thresholds.

In the present study, tumor PD-L1 expression and its association with the clinicopathological characteristics and survival outcomes of NPC were analyzed. The PD-L1 protein was found to be frequently expressed in NPC and high tumor expression of PD-L1 was prognostic for poor DFS. Fang *et al* ([@b25-mco-0-0-1318]) reported that 89% (16/18) of EBV-associated NPC cases expressed PD-L1 in the malignant tumor cells, which is consistent with the findings of our study. Additionally, high expression of PD-L1 was also found to be associated with poor clinical prognosis in renal cell carcinoma, hepatocellular cancer and breast cancer ([@b26-mco-0-0-1318]--[@b29-mco-0-0-1318]).

Previous studies demonstrated that constitutively-activated oncogenic pathways may upregulate PD-L1. Parsa *et al* reported loss of phosphatase and tensin homolog and resulting activation of the phosphoinositide 3-kinase pathway significantly upregulates PD-L1 in glioma ([@b30-mco-0-0-1318]). Marzec *et al* found constitutive activation of nucleophosmin/anaplastic lymphoma kinase induces PD-L1 expression via signal transducer and activator of transcription 3 ([@b31-mco-0-0-1318]). The mechanism through which PD-L1 is upregulated in NPC has not been fully elucidated. Fang *et al* observed that high levels of PD-L1 expression in EBV-infected NPC cells were associated with latent membrane protein 1 (LMP1)-mediated oncogenic pathways and immune modulation via excretion of interferon-γ ([@b25-mco-0-0-1318]). These results indicated that inhibition of the LMP1 oncogenic pathway and PD-1/PD-L1 checkpoints may provide a clinical benefit during the treatment of EBV-associated NPC.

In conclusion, PD-L1 is frequently upregulated in NPC, and high PD-L1 expression was associated with poor prognosis. These findings implicate PD-L1 in the development of NPC and highlight the potential of PD-L1 as a therapeutic target for NPC. Patients with NPC whose tumors express high levels of PD-L1 may be optimal candidates for clinical trials of strategies aiming to block PD-L1.
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![Representative images of immunohistochemical staining for programmed death ligand 1 (PD-L1) in nasopharyngeal carcinoma (NPC). (A) PD-L1 was expressed in the cell membrane of the primary tumor cells (magnification, ×40). (B and C) The PD-L1 protein was expressed in NPC cells, but not the surrounding normal nasopharyngeal epithelial cells (magnification, ×40). (D) PD-L1 was expressed in the germinal center of lymph nodes (magnification, ×40).](mco-07-03-0378-g00){#f1-mco-0-0-1318}

![Kaplan-Meier overall survival (OS) and disease-free survival (DFS) curves for the 62 patients eligible for survival analysis. (A) OS and (B) DFS curves for the 62 patients. (C) OS and (D) DFS curves for patients stratified by high and low PD-L1 expression. PD-L1, programmed death ligand 1.](mco-07-03-0378-g01){#f2-mco-0-0-1318}

###### 

Associations between PD-L1 expression and the clinicopathological characteristics of nasopharyngeal carcinoma.

                       PD-L1 expression        
  -------------------- ------------------ ---- -----------
  Sex                                          
    Male               40                 46   
    Female             14                 20   0.597
  Age, years                                   
    ≤45                9                  26   
    \>45               45                 40   **0.006**
  Smoking history                              
    No                 26                 28   
    Yes                18                 19   0.963
  Histology                                    
    Differentiated     29                 26   
    Undifferentiated   25                 40   0.118
  AJCC stage (2010)                            
    I--III             32                 47   
    IV                 15                 8    **0.036**
  T stage                                      
    T1/T2              17                 30   
    T3/T4              30                 25   0.063
  N stage                                      
    N0/N1              22                 17   
    N2/N3              25                 38   0.100

Pearson\'s Chi-squared test. Bold print indicates statistically significant values. AJCC, American Joint Committee on Cancer; PD-L1, programmed death ligand-1.

###### 

Univariate analysis of the associations between the clinicopathological characteristics of nasopharyngeal carcinoma and disease-free survival.

  Clinicopathological characteristics   Subset                                Hazard ratio (95% CI)   P-value
  ------------------------------------- ------------------------------------- ----------------------- -----------
  Gender                                Male vs. female                       1.322 (0.431--4.056)    0.626
  Age, years                            \>45 vs. ≤45                          1.747 (0.570--5.352)    0.329
  Smoking history                       No vs. yes                            0.785 (0.207--2.973)    0.722
  Histology                             Undifferentiated vs. differentiated   1.595 (0.521--4.886)    0.413
  AJCC stage                            IV vs. I--III                         1.662 (0.533--5.181)    0.381
  T stage                               T3/T4 vs. T1/T2                       4.081 (1.130--18.14)    **0.048**
  N stage                               N0/N1 vs. ≤ N2/N3                     0.530 (0.145--1.947)    0.339
  Neoadjuvant chemotherapy 1            TPF vs. TP/FP/other                   0.489 (0.134--1.792)    0.281
  Neoadjuvant chemotherapy 2            Includes NDP vs. DDP                  1.669 (0.451--6.181)    0.443
  Neoadjuvant chemotherapy 3            Yes vs. no                            0.832 (0.270--2.562)    0.749
  Radiotherapy                          CCRT vs. RT                           0.461 (0.149--1.426)    0.179
  Adjuvant chemotherapy                 2-3 vs. 0--1 cycles                   0.370 (0.113--1.218)    0.102
  PD-L1 expression                      Negative vs. positive                 0.163 (0.044--0.600)    **0.006**

Bold print indicates statistically significant values. AJCC, American Joint Committee on Cancer; CI, confidence interval; TPF, docetaxel + platinum + fluorouracil; TP, docetaxel + platinum; FP, fluorouracil + platinum; NDP, nedaplatin; DDP, cisplatin; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; PD-L1, programmed death ligand-1.
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